Aston University collaboration to develop injectable paste which could treat bone cancer

Feb 18, 2025

4 min

Professor Richard Martin
  • A £110k grant from Orthopaedic Research UK is to help to conduct the work
  • Study is a collaboration with The Royal Orthopaedic Hospital
  • Researchers to use gallium-doped bioglass to produce a substance with anticancer and bone regenerative properties.


              Professor Richard Martin



Aston University is collaborating in research to develop an injectable paste which could treat bone cancer.


The Royal Orthopaedic Hospital has secured a £110,000 grant from Orthopaedic Research UK to conduct the work. The project will see researchers at the hospital and the University use gallium-doped bioglass to produce a substance with anticancer and bone regenerative properties. If proved effective it could be used to treat patients with primary and metastatic cancer.


Gallium is a metallic element that when combined with bioactive glass can kill cancerous cells that remain when a tumour is removed. It also accelerates the regeneration of the bone and prevents bacterial contamination. A recent study led by Aston University found that bioactive glasses doped with the metal have a 99 percent success rate of eliminating cancerous cells.


Dr Lucas Souza, research lab manager at the hospital’s Dubrowsky Lab is leading the project. He said : “Advances in treatment of bone cancer have reached a plateau over the past 40 years, in part due to a lack of research studies into treatments and the complexity and challenges that come with treating bone tumours. Innovative and effective therapeutic approaches are needed, and this grant provides vital funds for us to continue our research into the use of gallium-doped bioglass in the treatment of bone cancer.”


Professor Richard Martin who is based in Aston University’s College of Engineering and Physical Sciences added: “The injectable paste will function as a drug delivery system for localised delivery of anticancer gallium ions and bisphosphonates whilst regenerating bone. Our hypothesis is that this will promote rapid bone formation and will prevent cancer recurrence by killing residual cancer cells and regulating local osteoclastic activity.”


It is hoped the new approach will be particularly useful in reducing cancer recurrence and implant site infections. It is also thought that it will reduce implant failure rates in cases of bone tumours where large resections for complete tumour removal is either not possible, or not recommended. This could include incidents when growths are located too close to vital organs or when major surgery will inflict more harm than benefit. It could also be used in combination with minimally invasive treatments such as cryoablation or radiofrequency ablation to manage metastatic bone lesions.


Dr Souza added: “The proposed biomaterial has the potential to drastically improve treatment outcomes of bone tumour patients by reducing cancer recurrence, implant-site infection rates, and implant failure rates leading to reduced time in hospital beds, less use of antibiotics, and fewer revision surgeries. Taken together, these benefits could improve survival rates, functionality and quality of life of bone cancer patients.”


Other members of the team include the hospital’s Professor Adrian Gardner, director of research and development and Mr Jonathan Stevenson, orthopaedic oncology and arthroplasty consultant, Dr Eirini Theodosiou from Aston University and Professor Joao Lopes from the Brazilian Aeronautics Institute of Technology.


ENDS


About the Royal Orthopaedic Hospital NHS Foundation Trust

The Royal Orthopaedic Hospital NHS Foundation Trust is one of the largest specialist orthopaedic units in Europe, offering planned orthopaedic surgery to people locally, nationally, and internationally.

The Trust is an accredited Veteran Aware organisation and a Disability Confident Leader. Ranked 8th in the 2024 UK Inclusive Top 50 Employers list, the Royal Orthopaedic Hospital is the highest-ranking NHS organisation for its commitment to diversity and inclusion.

The Royal Orthopaedic Hospital has a vibrant research portfolio of clinical trials, observational studies and laboratory studies exploring new treatment options, new approaches in rehabilitation and therapy, and new medical devices. This research is delivered by our researchers and clinicians spread across the Knowledge Hub, our home for education and research, and the Dubrowsky Regenerative Medicine Laboratory, a state-of-the-art lab opened in 2019.


About Aston University

For over a century, Aston University’s enduring purpose has been to make our world a better place through education, research and innovation, by enabling our students to succeed in work and life, and by supporting our communities to thrive economically, socially and culturally.

Aston University’s history has been intertwined with the history of Birmingham, a remarkable city that once was the heartland of the Industrial Revolution and the manufacturing powerhouse of the world.

Born out of the First Industrial Revolution, Aston University has a proud and distinct heritage dating back to our formation as the School of Metallurgy in 1875, the first UK College of Technology in 1951, gaining university status by Royal Charter in 1966, and becoming The Guardian University of the Year in 2020.

Building on our outstanding past, we are now defining our place and role in the Fourth Industrial Revolution (and beyond) within a rapidly changing world.

For media inquiries in relation to this release, contact Nicola Jones, Press & Communications Manager on 07941194168 or email: n.jones6@aston.ac.uk


Connect with:
Professor Richard Martin

Professor Richard Martin

Reader, Electrical, Electronic & Power Eng, Aston Institute of Materials Research (AIMR)

Dr Martin's research interests include bioactive glass and structural studies.

Advanced ImagingStructural StudiesBioactive GlassGlassNeutron Scattering
Powered by

You might also like...

Check out some other posts from Aston University

2 min

Aston University economists say Prime Minister can reduce UK trade vulnerability with China visit

Greenland episode exposed UK’s lack of effective response to economic coercion from allies Research shows tariff retaliation would have cost the average UK household up to £324 per year Economists say China visit is “portfolio risk management” – diversification reduces vulnerability. The Prime Minister’s visit to China – the first by a British PM since 2018 – is an opportunity to reduce the UK’s vulnerability to economic coercion, according to new research from Aston University. A policy paper from Aston Business School’s Centre for Business Prosperity analyses the January 2026 Greenland tariff episode, when President Trump threatened and then withdrew tariffs on eight European countries. The researchers found that the UK had no good options: retaliation would have made Britain worse off, while absorbing the tariffs left Europe without credible deterrence. Director of the centre for business prosperity, Professor Jun Du, said: “The Greenland episode was a wake-up call. When your principal security ally threatens economic coercion, the old assumptions about who is safe and who is dangerous no longer hold. “The PM’s China visit should be framed as portfolio risk management – building diversified trading relationships that reduce the UK’s exposure to any single partner. Just as investors don’t put all their money in one stock, countries shouldn’t put all their trade into one basket. A UK with multiple strong partnerships is harder to pressure, whether the pressure comes from Washington or Beijing.” The research found that coordinated UK–EU tariff retaliation would have cost British households up to £324 per year – the worst outcome modelled. But the authors argue that Europe has untapped leverage elsewhere: the US runs a €148 billion annual services surplus with the EU, and mutual investment exceeds €5.3 trillion. Associate professor of economics and co-author, Dr Oleksandr Shepotylo, said: “Tariff retaliation fails because it hurts consumers and distorts the economy – the retaliator suffers similarly to the target. But Europe has cards it isn’t playing. Services, investment screening, and regulatory access are pressure points where Europe can respond effectively.” UK exports to China fell by 10.4% in the year to Q2 2025, with goods exports down 23.1% – the sharpest decline among major trading partners. The researchers argue that this closes off the UK’s largest alternative market at precisely the moment US reliability is in question. The paper identifies three priorities for UK policy: Recognise the permanent incentives behind US tariffs. US tariff revenue hit $264 billion in 2025. Trade negotiations alone cannot resolve revenue-driven policy. Build UK–EU coordination on non-tariff instruments. Services, investment, procurement, and regulation offer leverage that tariffs do not. Treat China engagement as portfolio risk management. Concentration in any single market creates vulnerability. Diversification is not about picking sides – it’s about resilience. Professor Du added: “The question for the Prime Minister is whether to use this breathing space to build resilience – or wait for the next Greenland.” To read the policy paper in full, click on this link:

2 min

Medication adherence: Why it matters and how we can improve it – public lecture by Professor Ian Maidment

Professor Ian Maidment is a professor in clinical pharmacy at Aston Pharmacy School His inaugural lecture will explain why patients struggle with taking medication and present possible solutions to the problem Professor Maidment is a former practising pharmacist and an expert in medication optimisation and management in mental health and dementia. Professor Ian Maidment, professor in clinical pharmacy at Aston Pharmacy School, will give a public lecture about his life’s work on 5 February 2025. In his inaugural lecture, Professor Maidment will reflect on his journey from a childhood in Kent to becoming a leading researcher in clinical pharmacy. After more than two decades working in the NHS, in community pharmacy, mental health, dementia care, and leadership roles, he joined Aston University in 2012. His research focuses on the real-world challenges of medication optimisation for patients, carers, and healthcare professionals. The title of Professor Maidment’s lecture is ‘Medication adherence: Why it matters and how we can improve it’. Every year, the UK spends nearly £21 billion on medicines. Yet up to half of people with long-term conditions do not take their medication as prescribed—a problem known as non-adherence. This has profound clinical consequences and significant financial implications for the NHS. Professor Maidment will draw on his experience to explore how factors such as medication burden and side-effects influence adherence, the challenges posed by conditions such as dementia and severe mental illness, the role of pharmacy in supporting adherence and why tackling non-adherence requires a system-wide approach. He will also offer practical solutions to one of healthcare’s most persistent problems. Professor Maidment said: “We need to understand why patients struggle to take their medication and then develop and test solutions that work well.” The lecture on Thursday 5 February 2026 will take place at Aston Business School. In-person tickets are available from Eventbrite. The public lecture will begin at 18:00 GMT with refreshments served from 17:30 GMT. It is free of charge and will be followed by a drinks reception. The lecture will also be streamed online.

3 min

New research partnership to develop biodegradable gloves from food waste for healthcare sector

Knowledge Transfer Partnership between Aston University and PFE Medical to develop a biodegradable clinical glove from food waste The gloves will provide a low-cost, convenient and sustainable alternative to the 1.4bn disposable gloves used in the NHS each year The innovation will reduce clinical waste and costs and help the NHS reach its net zero goals. Aston University and Midlands-based company PFE Medical are teaming up to create biodegradable gloves made from food waste for use in the NHS. They will offer a low-cost, convenient alternative to disposable gloves without compromising patient safety. More than 1.4bn disposable gloves are used by the NHS each year. They create large volumes of clinical waste which has both an environmental and economic cost. The Knowledge Transfer Partnership (KTP) project will develop a more sustainable alternative made from polymers derived from food waste such as orange peel, able to degrade naturally. The gloves will initially be for use during low-risk tasks such as ultrasound scans, rather than in more critical situations such as operating theatres. The gloves would be designed to not only reduce clinical waste and costs in the NHS, but also carbon emissions, helping the NHS reach its goal to be the world’s first net-zero health service. With most personal protective equipment (PPE) currently sourced from Chinese manufacturers, the goal is to develop a biodegradable glove that can be manufactured using a UK supply chain. The challenging project draws on Aston University’s expertise in sustainable polymer chemistry, centred at Aston Institute for Membrane Excellence (AIME). Aston University has one of the largest research groups of polymer chemists in the UK. The project will be led at the University by Professor Paul Topham, director of AIME, and Dr James Wilson, AIME associate member. The research team have chosen to focus on polymers from food waste in order to ensure that the final product can be manufactured sustainably. Most polymers are currently made from petroleum. Polymers made from food waste, ranging from fruit waste to corn or dairy products, have the potential for antioxidant and antibacterial properties if designed appropriately. The team will manipulate the polymer molecules so that they include the right monomers (the smaller units which make up the molecules) in the right location to achieve the properties they require. Critical to the success of the project will be PFE Medical’s commercial and clinical experience of taking new innovations into medical use. It will be the third KTP between Aston University and PFE, following on from successful projects to develop an automated endoscope cleaner, now in use across University Hospitals Birmingham NHS Foundation Trust (UHB). Professor Topham said: “At Aston University, we have a long history of working with industry, of translating fundamental research into solutions for real world problems. This project with PFE Medical provides us with that route, to take our science and engineering and make a difference to peoples’ lives. That’s exactly where, as researchers, we want to be.” Rob Hartley, CEO of PFE Medical, said: “Our previous KTP with Aston University was a phenomenal success, thanks to the brilliant team we had on board. I’m just as excited by this project, which is looking to solve an equally long-standing problem. If we can achieve our goal, then the implications are huge, going far beyond the NHS to all the other situations where people are wearing disposable gloves.” KTPs, funded by Innovate UK, are collaborations between a business, a university and a highly qualified research associate. The UK-wide programme helps businesses to improve their competitiveness and productivity through the better use of knowledge, technology and skills. Aston University is a sector-leading KTP provider, ranked first for project quality, and joint first for the volume of active projects. For further details about this KTP, visit the webpage: www.aston.ac.uk/business/collaborate-with-us/knowledge-transfer-partnership/at-work/pfe-medical.

View all posts